{
"endpoint": "clinicaltrials",
"count": 1,
"truncated": true,
"took_ms": 3178,
"items": [
{
"recordType": "study",
"nctId": "NCT02654665",
"title": "Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults",
"officialTitle": "Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults",
"acronym": "CGH-LiNASH",
"status": "UNKNOWN",
"lastKnownStatus": "RECRUITING",
"studyType": "INTERVENTIONAL",
"phases": [
"PHASE3"
],
"conditions": [
"Non-alcoholic Fatty Liver Disease (NAFLD)",
"Weight Loss",
"Non-alcoholic Steatohepatitis (NASH)"
],
"interventions": [
"Lifestyle modification",
"Liraglutide"
],
"interventionTypes": [
"BEHAVIORAL",
"DRUG"
],
"leadSponsor": "Changi General Hospital",
"sponsorClass": "OTHER",
"enrollmentCount": 36,
"enrollmentType": "ESTIMATED",
"startDate": "2014-03",
"primaryCompletionDate": "2017-12",
"completionDate": "2018-12",
"firstPosted": "2016-01-13",
"lastUpdatePosted": "2018-01-30",
"sex": "ALL",
"minimumAge": "21 Years",
"maximumAge": "65 Years",
"healthyVolunteers": true,
"locationCount": 1,
"countries": [
"Singapore"
],
"locations": [
"Changi General Hospital, Singapore, Singapore"
],
"primaryOutcomeMeasures": [
"Improvement in NASH"
],
"briefSummary": "Non-alcoholic fatty liver disease (NAFLD) is defined by presence of hepatic steatosis (fat accumulation in liver cells), either by imaging or by biopsy and absence of causes for secondary hepatic fat accumulation such as significant alcohol consumption, medications, or hereditary disorders. In the majority of patients, NAFLD is associated with risk factors for cardiovascular disease such as obesity, diabetes mellitus, and high cholesterol, and may lead to irreversible liver damage. Non-alcoholic steatohepatitis (NASH) is a more severe form of NAFLD and is present in up to 30% of obese adults. NASH is defined by hepatic steatosis and inflammation with hepatocyte injury with or without fibrosis (hardening of the liver).\n\nThe prevalence, morbidity and mortality of NAFLD is increasing, particularly in the Asia-Pacific region where there will be an estimated 300 million obese people by 2030. Weight loss is the first-line treatment for NAFLD in obese individuals, but the utility of lifestyle modification with diet and exercise is limited by difficulties in sustaining compliance and by eventual weight regain. Bariatric (weight loss) surgery produces the greatest amount of weight loss but is limited by cost, patient acceptance, and complications. The efficacy of drugs for NASH, such as vitamin E and medication to lower cholesterol and glucose, remains unclear. Liraglutide, a glucagon-like peptide (GLP-1) analogue, is an injectable medication which has been shown to induce weight loss and lower glucose in obese adults. There is little information on the effects of GLP-1 analogues on NASH, particularly in comparison to other modalities of weight loss such as surgery. This study aims to compare the efficacy and safety of lifestyle modification, liraglutide and surgery, for weight loss in conjunction with reducing severity of NASH, and for insulin resistance, high cholesterol and other cardiovascular risk factors.",
"eligibilityCriteria": "Inclusion Criteria:\n\n* Body mass index \\> 27.5 kg/m2\n* Waist circumference (WC) \\> 90 cm (male) or \\> 80 cm (female)\n* Diagnosis of NASH based on Liver Function Test Results ,Ultrasound Hepato-Biliary System (HBS) findings and / or Liver Biopsy\n* HbA1c \\< 8%\\* \\*Subjects in the bariatric surgery arm will not need to fulfil this criterion.\n\nExclusion Criteria:\n\n* Currently using insulin-sensitising agents (metformin, pioglitazone), weight loss medication (orlistat, phentermine). Patients taking any of these drugs will require a three month washout period before enrolment.\n* Pregnancy\n* Significant cardiovascular or respiratory disease\n* Renal impairment with eGFR \\< 60 ml/min\n* Hepatitis B or C carrier, liver disease other than NAFLD\n* History of pancreatitis\n* Personal or family history of multiple endocrine neoplasia type 2 or thyroid carcinoma\n* Untreated hypothyroidism or hyperthyroidism\n* Current psychiatric illness\n* Cardiac pacemaker, metallic prosthetic heart valves and other contraindications to MRI scan\n* Current smoker\n* Alcohol intake ≥ 14 units/week",
"url": "https://clinicaltrials.gov/study/NCT02654665",
"scrapedAt": "2026-11-11T16:07:29.999Z"
}
]
}
curl --location --request GET 'https://zylalabs.com/api/14932/clinical+trial+studies+api/39019/search+clinical+trial+studies?query=diabetes&limit=2' --header 'Authorization: Bearer YOUR_API_KEY'
साइन अप करने के बाद, प्रत्येक डेवलपर को एक पर्सनल API एक्सेस की असाइन की जाती है, जो अक्षरों और अंकों का एक यूनिक संयोजन होता है, जिसका उपयोग हमारे API एंडपॉइंट तक पहुंचने के लिए किया जाता है। प्रमाणीकरण के लिए क्लिनिकल ट्रायल अध्ययन API के साथ बस अपने बेयरर टोकन को Authorization हेडर में शामिल करें।
| हेडर | विवरण |
|---|---|
Authorization
|
आवश्यक
होना चाहिए Bearer access_key. जब आप सब्सक्राइब हों तो ऊपर "Your API Access Key" देखें।
|
कोई लंबी अवधि की प्रतिबद्धता नहीं। कभी भी अपग्रेड, डाउनग्रेड या कैंसल करें।
(वार्षिक बिलिंग के साथ 2 महीने बचाएँ 🎉)
पंजीकृत नैदानिक अध्ययन NCT आईडी, शीर्षक, स्थिति, चरण, प्रायोजक, परिस्थितियाँ और तिथियाँ।
प्रत्येक प्रतिक्रिया JSON होती है जिसमें एक गिनती होती है एक took_ms फ़ील्ड और फ़्लैट रिकॉर्ड का एक आइटम ऐरे होता है जो संग्रहित या क्वेरी करने के लिए तैयार होता है
नहीं अनुरोध सर्वर-साइड पर प्रबंधित किए जाते हैं आप केवल अपनी एपीआई कुंजी और इस एंडपॉइंट में वर्णित पैरामीटर भेजते हैं
हर कॉल स्रोत को वास्तविक समय में पढ़ता है इसलिए रिकॉर्ड अनुरोध समय पर उपधारा स्रोत की स्थिति को दर्शाते हैं
आपको एक स्पष्ट त्रुटि स्थिति मिलती है न कि एक खाली परिणाम इसलिए एक विफलता को कभी भी डेटा की कमी के रूप में गलत नहीं समझा जाता
हाँ प्रत्येक एंडपॉइंट प्रत्येक अनुरोध में रिकॉर्ड की संख्या को सीमित करता है अधिकतम सीमा पैरामीटर में दी गई है